Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen
Status:
Recruiting
Trial end date:
2023-03-11
Target enrollment:
Participant gender:
Summary
Currently,6 cycles of Temozolomide adjuvant chemotherapy after concurrent radiotherapy and
Temozolomide chemotherapy(STUPP regimen)for newly diagnosed postoperative GBM can increase
the 2-year and 5-year overall survival rates of patients to 26.5% and 9.8%, respectively.
However, most patients are still unable to avoid tumor recurrence and death.Anlotinib is an
efficient multi-target tyrosine kinase inhibitor (TKI) that effectively block the migration
and proliferation of endothelial cells and reduce tumor microvascular density by targeting
VEGFRs, FGFRs, PDGFRs. It has been proved to be safe and effective in advanced lung
cancer(including NSCLC,SCLC)after second-line standard chemotherapy failure,and advanced soft
tissue sarcoma after anthracycline-containing chemotherapy failure.Here, we prepared to
evaluate whether the combination of dose-dense Temozolomide and Anlotinib can preferably
improved survival of the first recurrent or progressive GBM after STUPP regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Yonggao Mou
Collaborator:
The First Affiliated Hospital of Nanchang University